SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (3973)12/21/1997 2:01:00 PM
From: LoLoLoLita  Read Replies (1) of 23519
 
>>100 mg dose study just published in the Journal of Urology
>>in November or December issue, from Brazil with no FDA to
>>protect patients from high dose (this is probably the
>>highest dose used for Yohimbine in a formal study)

Cacaito--

100 mg? My Lord!, those people should called "victims" not
"patients"!!! How many ended up in the ER/ICU with
hypotensive shock?

Don't the pharmacists have an old saw that "the only difference
between a drug and a poison is in the dose"?

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News